NR 607 Week 8 Comprehensive Exam Study Guide

• Support social programs • Medica琀椀on adverse e昀昀ect iden琀椀昀椀ca琀椀on (presenta琀椀ons) • Medica琀椀on AE management (muscular AE related to an琀椀psycho琀椀c use) o Parkinsonism, tardive dyskinesia o Metabolic concerns related to medica琀椀ons- includes management. • Treatment failure • LAI- risks and bene昀椀ts, ini琀椀a琀椀on techniques • Switching an琀椀psycho琀椀cs Treatment-resistant depression (TRD) • Star *D criteria and recommenda琀椀ons • Iden琀椀昀椀ca琀椀on, treatment, supplements • Nonpharmacological treatments (TMS,ECT, deep brain s琀椀mula琀椀on ) Demen琀椀a- iden琀椀昀椀ca琀椀on, comorbidi琀椀es and treatment (includes symptom management) 4 No content- 5 Social Determinates of Health 6 Disorders- iden琀椀昀椀ca琀椀on and treatment & what are the Boland, R., & Verduin, di昀昀erences M. L. (2022). Kaplan and • Soma琀椀c Sadock's synopsis of • Illness anxiety psychiatry (12th ed.). Wolters Kluwer. • Conversion • Chapter 11: • Fac琀椀琀椀ous Dissociative Disorders Dissocia琀椀ve Disorders Chapter 11 • Chapter 12: Somatic • What is dissocia琀椀ve amnesia, dissocia琀椀ve Symptom and Related fugue, types of amnesia Table 11-1 , Treatment Disorders for dissocia琀椀ve amnesia Wheeler, (2022) Soma琀椀c & Illness Anxiety Disorder Chapter 12 • What is soma琀椀c symptom disorder, illness • Chapter 17: Stabilization for anxiety disorder, and conversion disorder, Trauma and Dissociation fac琀椀琀椀ous disorder Chapter 17 (Wheeler) Stabiliza琀椀on for Trauma and Dissocia琀椀on • What is the resilience zone • What are the goals of treatment for trauma • What are outcome scales for dissocia琀椀on? 7 Polyvagal theory Stahl (2021) Chapter 8 Anxiety, • involved neural pathways. trauma and treatment Violence • protec琀椀ve factors • risk factors Droperidol is FDA–approved for treatment of anxiety and for seda琀椀on. Three drugs are FDA–approved for the treatment of acute agita琀椀on associated with schizophrenia and bipolar I disorder: intramuscular (IM) olanzapine, IM ziprasidone, and loxapine inhala琀椀on powder. The overall e昀케cacy in achieving tranquiliza琀椀on is equivalent among an琀椀psycho琀椀cs, with di昀昀erences in adverse e昀昀ect pro昀椀les. FGAs carry a higher risk for adverse extrapyramidal symptoms, dystonia, and prolonged QTc. Droperidol has a FDA boxed warning for QTc prolonga琀椀on; however, the warning does not apply for the lowest dose of 2.5 mg; thus, the drug has regained popularity as a safe and e昀昀ec琀椀ve treatment for severe agita琀椀on (Ma琀琀son et al., 2020; Perkins et al., 2015). Loxapine carries a FDA black box warning for bronchospasms and should not be given to pa琀椀ents with lung diseases (Listen to selec琀椀onU.S. FDA, 1975) Merck manual Clozaril link h琀琀ps://www.merckmanuals.com/professional/drug-names-generic-and-brand